I hereby certify that this correspondence is being filed via EFS-Web with the United States Patent and Trademark Office on \_\_\_\_\_ June 7, 2007

PATENT Attorney Docket No.: 021819-000130US Client Reference No.: JUV2879.54-3

TOWNSEND and TOWNSEND and CREW LLP

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Steven W. Dow, et al.

Application No.: 10/780,114

Filed: February 17, 2004

For: SYSTEMIC IMMUNE ACTIVATION METHOD USING

NUCLEIC ACID-LIPID COMPLEXES

Customer No. 20350

Confirmation No.: 8036

Examiner: A Webbe

Art Unit: 1633

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER

37 CFR §1.97 and §1.98

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08B are being called to the attention of the Examiner. Copies of the references in compliance with the requirements of 37 CFR §1.98(a)(2) are enclosed.

It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR \$1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

Steven W. Dow, et al. Application No.: 10/780,114

Page 2

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

This IDS is being filed before the mailing date of the final Office Action or Notice of Allowance.

Please charge the IDS fee of \$180 to Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,
Karen Babyak Dows

Karen B. Dow Reg. No. 29,684

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, Eighth Floor San Francisco, California 94111-3834 Tel: 858-350-6100

Fax: 415-576-0300 KBD:tsp

61069927 v1

Substitute for form 1449B/PTO				Complete if Known		
				Application Number	10/780.114	
INFO	RMATION	DISCLOS	URE	Filing Date	February 17, 2004	
STATEMENT BY APPLICANT (Use as many sheets as necessary)				First Named Inventor	Dow, Steven W.	
				Art Unit	1633	
				Examiner Name	A. Wehbe	
Sheet	1	of	1	Attorney Docket Number	021819-000130US	

NON PATENT LITERATURE DOCUMENTS							
Examiner Initials *	Cite No.1						
	ВА	AUF, Gregor, et al. "Implication of Macrophages in Tumor Rejection Induced by CpG- oligodeoxynucleotides Without Antigen", Clinical Cancer Research (2001) 7:3540-3543					
	ВВ	VOLLMER, Jörg, et al. "Oligodeoxynucleotides lacking CpG dinucleotides mediate Toll-like receptor 9 dependent Thelper type 2 biased immune stimulation", <i>Immunology</i> (2004) 113:212-223					
	вс						
	BD						
	BE						
	BF						
••••••	ВG						
	вн						
	ВІ						
	BJ						

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not obtation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

\*\*Applicant's unique clatifor designation number (opinion)\*\*\*Applicant's unique clatifor designation number (opinion)\*\*\*Applicant's unique clatifor designation is attached.